We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 32.00 | 1.91% | 1,705.00 | 1,701.00 | 1,701.50 | 1,718.50 | 1,673.00 | 1,685.50 | 5,853,296 | 16:35:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.21 | 70.03B |
From May 2021 to May 2024
By Chris Wack
GlaxoSmithKline Plc said the U.S. Food and Drug Administration has approved Shingrix for the prevention of shingles in adults aged 18 years and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy.
The company said Shingrix, a non-live, recombinant sub-unit adjuvanted vaccine given intramuscularly in two doses, was initially approved by FDA in 2017 for the prevention of shingles in adults 50 years of age or older.
Shingrix isn't indicated for prevention of primary varicella infection, or chickenpox. The approval for this new population expands the number of people who can be protected against shingles by Shingrix.
Glaxo said the approval for a new population was based on clinical studies examining the safety and efficacy of Shingrix in adults who had undergone an autologous hematopoietic stem cell transplant and those undergoing treatment for hematological malignancies.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 26, 2021 10:13 ET (14:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
